GLOW
GLOW is a tri-peptide regeneration matrix combining BPC-157, TB-500, and GHK-Cu in research-optimized ratios.
- Vial Size
- 70mg
- Molecular Weight
- Blend · 70 mg total payload
- Half-life
- Mixed pharmacokinetics across components
- Latest Lot Purity
- 99.59%
Mechanism of Action
GLOW is a tri-peptide regeneration matrix combining BPC-157, TB-500, and GHK-Cu in research-optimized ratios. The blend is intended to study cooperative effects across angiogenic, actin-binding, and copper-mediated remodeling pathways from a single reconstituted formulation.
Research Context
- Multi-pathway repair model research
- Dermal and connective tissue regeneration
- Copper-mediated remodeling studies
- Combined growth-factor signalling research
Lot NX-007 · Verified at 99.59%
Plasma Profile & Protocol
Modelled plasma concentration over time, reconstitution calculator, and a literature-derived research protocol for GLOW.
Illustrative Bateman model derived from published half-life and absorption data. For research-context visualisation only.
Solve for syringe units assuming a U-100 insulin syringe. Defaults seeded from the GLOW monograph.
U-100 insulin syringe assumed (100 units = 1 mL). For research dosing visualisation only. Verify all dilutions independently.
- Typical Dose
- 300–600 mcg blend
- Frequency
- Once daily
- Cycle Length
- 4–6 weeks
- Route
- Subcutaneous
Note ·Combined regeneration matrix; dose refers to blend volume.
Related Compounds
All compounds →
BPC 157
Research peptide used across tissue and recovery models.
TB 500
Thymosin beta fragment for connective tissue and repair studies.
KLOW
Four-peptide recovery matrix · GHK-Cu + TB-500 + BPC-157 + KPV
For Research Use Only · This monograph summarises publicly available research literature for educational, in-vitro and laboratory research purposes only. Nexora Labs products are not drugs, food, supplements, or cosmetics, and are not intended to diagnose, treat, cure or prevent any condition.